Drug Design; G-Protein-Coupled Receptor Kinase 2/antagonists & inhibitors; Protein Kinase Inhibitors/pharmacology; Dose-Response Relationship, Drug; G-Protein-Coupled Receptor Kinase 2/metabolism; Humans; Magnetic Resonance Spectroscopy; Models, Molecular; Protein Kinase Inhibitors/chemical synthesis; Protein Kinase Inhibitors/chemistry; Structure-Activity Relationship

2,2,4,6,7­pentamethyldihydro benzofuran-5-sulfonyl; 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-phosphate; 9-fluorenyl-methoxycarbonyl; ATP; Cardiovascular system; Cyclic peptides; DCM; DIPEA; DMF; DPC; EDTA; EGTA; ESI; Ethylene diamine tetraacetic acid; Fmoc; GRK2 inhibitors; HBTU; HOBt; LCQ; N,N-diisopropylethyl-amine; N,N-dimethylformamide; N-hydroxy-benzotriazole; NMR conformational analysis; Pbf; Pr(3)SiH or TIS; RP-HPLC; SAR; TFA; Trt; adenosine triphosphate; cAMP; cyclic adenosine monophosphate; dichloromethane; dodecylphosphocholine; electrospray ionization; ethylene glycol tetraacetic acid; liquid chromatography quadrupole mass spectrometry; reversed-phase high performance liquid chromatography; structure­activity relationship; trifluoroacetic acid; triisopropylsilane; trityl